VRG Therapeutics is an innovative biotechnology company headquartered in Budapest, focused on the discovery and development of next-generation miniprotein therapeutics targeting challenging biological mechanisms. The company leverages its proprietary AI-MPRO platform, which integrates computational protein design, high-throughput screening, and machine learning–driven analytics to generate highly selective and potent drug candidates. With a strong scientific foundation and an experienced team, VRG Therapeutics is advancing a growing pipeline of therapeutic programs with the potential to deliver differentiated best-in-class and first-in-class treatments.
The collaboration combines VRG’s AI platform with AOP Health’s expertise in rare diseases and immunology to develop a highly selective therapeutic targeting Kv1.3-mediated immune dysfunction.